Pancreatic cancer

Pancreatic cancer cells can change their ‘diet’ to keep growing, by switching from the sugar glucose to a back-up fuel called uridine, new research has revealed. The findings suggest that blocking the availability of uridine using new drugs could become a new treatment strategy for the most common and aggressive form of pancreatic cancer. The […]

A Spanish study has shown that PRP, a mixture of two proenzymes, trypsinogen and chymotrypsinogen, suppresses the TGF-β pathway and the tumour microenvironment in pancreatic cancer. The study was co-led by Belén Toledo Cutillas, at the laboratory of Professor Macarena Perán, University of Jaén, Granada, Spain. The experiments were conducted with a well-known small molecule […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have seen a number of developments in the treatment of solid tumours hitting the headlines. Pennsylvania researchers may have found […]

News round-up for 20-24 March by DDW Digital Content Editor Diana Spencer.  This week we have seen a number of developments in the treatment of solid tumours hitting the headlines. Pennsylvania researchers may have found a way to boost CAR-T therapy in these tumours, previously only successful in blood cancers, which could have huge implications for […]

Purple Biotech has revealed positive new results from exploratory analyses conducted as part of a Phase I dose escalation study into CM24 plus nivolumab for advanced cancer. The study enrolled 14 patients with advanced cancers including 11 patients with pancreatic adenocarcinoma (PDAC), two patients with colorectal adenocarcinoma (CRC) and one patient with papillary thyroid cancer. […]

SiSaf is to collaborate with the University of Leipzig, Germany, to develop targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer.   The collaboration will combine SiSaf’s expertise in RNA delivery using its Bio-Courier silicon-stabilised hybrid lipid nanoparticles (sshLNPs) and the University of Leipzig’s expertise in miRNA targeting […]

A novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, has significantly improved anti-tumour responses in preclinical models of pancreatic cancer.  In the study, published in Nature Cancer, researchers at The University of Texas MD Anderson Cancer Center used comprehensive immune profiling in mouse and human pancreatic cancers to systematically identify […]

News round-up for 24-28 October by DDW Digital Content Editor Diana Spencer  Over the last seven days we’ve seen discoveries that could lead to new treatments for Covid-19, pancreatic cancer and Epstein-Barr virus, as well as the launch of the UK’s largest health research programme and the innovative application of a Nobel prize-winning chemistry technique.  This week’s top […]

Biomedical engineers at Duke University have demonstrated the most effective treatment for pancreatic cancer ever recorded in mouse models.  The new treatment completely eliminated tumours in 80% of mice across several model types, including those considered the most difficult to treat.  The approach combines traditional chemotherapy drugs with a new method for irradiating the tumour. […]

DDW Deputy Editor Reece Armstrong takes a look at some of the biggest developments that took place within oncology this week (4 April – 8 April).  Scientists win award for transforming breast cancer treatment  A team of scientists from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust has won a […]

Biotechnology company RedX is collaborating with the Garvan Institute of Medical Research on a project investigating novel therapeutic targets in cancer-associated fibrosis.  The collaboration aims to better understand treatments that could lead to increased patient survival in currently very poorly treated highly fibrotic cancers, such as pancreatic cancer.   Redx and Garvan will work on developing […]